Although the median OS has not yet been reached, the clinical outcomes from our study generally compare favorably to published reports of frontline regimens using dual anti–PD-1 or PD-L1 and anti–CTLA-4 inhibition for NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.